Market Cap 2.12B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 45,397,746
Avg Vol 6,656,706
Day's Range N/A - N/A
Shares Out 306.61M
Stochastic %K 97%
Beta 1.20
Analysts Strong Sell
Price Target $10.75

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
tradersunion353
tradersunion353 Aug. 10 at 9:21 PM
$ABCL what a unimpressive move who cares how good data is when stock does not benefit real share holders clowns here are just married to ABCL . they are not real share holders
0 · Reply
ShangVXO
ShangVXO Aug. 10 at 9:19 PM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $HIMS / $ABCL profit makers
0 · Reply
Instwr
Instwr Aug. 10 at 9:16 PM
$ABCL price target moved to 30$ by TRUIST analysts!
0 · Reply
dzetom
dzetom Aug. 10 at 9:10 PM
$ABCL If the 12-week data preserve efficacy, Phase III design is agreed with FDA without complications, and liver safety remains clean, I think a rerating into the $20–25 range before approval becomes quite plausible. Actual approval with genuinely best-in-class Phase III data could eventually justify a valuation well above $25, particularly because ABCL would then also have validated its broader internal drug-development platform.
0 · Reply
Stef_Gee
Stef_Gee Aug. 10 at 9:10 PM
$ABCL 🤔
1 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 10 at 8:56 PM
$ABCL $ABCL Two new analyst rating updates today: 5-star analyst Debanjana Chatterjee upgrades her street high target from $13 to $25. 5-star analyst Srikripa Devarakonda reiterates a buy rating:
0 · Reply
jerrybe5000
jerrybe5000 Aug. 10 at 8:52 PM
$ABCL surprised they haven’t announce a share issuance yet!
0 · Reply
saleen18
saleen18 Aug. 10 at 8:50 PM
$ABCL People taking pills now for hot flashes is next level. My wife just uses ice packs
1 · Reply
Jwa68
Jwa68 Aug. 10 at 8:43 PM
$ABCL Nice tape boys. As anticipated.
1 · Reply
Money_maker777
Money_maker777 Aug. 10 at 8:36 PM
$ABCL Huge day for us holders. TradingView bumped their 1 year max target to $30, and that’s them being conservative the momentum we’re seeing could push us there way sooner. This one has real long term potential. And to all the new watchers showing up today, welcome to the party.
0 · Reply
Latest News on ABCL
AbCellera Biologics Slides: Corporate presentation

Aug 10, 2026, 8:00 AM EDT - 9 hours ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Transcript: Study result

Aug 10, 2026, 7:30 AM EDT - 9 hours ago

AbCellera Biologics Transcript: Study result


AbCellera Biologics Press release: Study result

Aug 10, 2026, 7:30 AM EDT - 9 hours ago

AbCellera Biologics Press release: Study result


AbCellera Biologics Slides: Study result

Aug 10, 2026, 7:30 AM EDT - 9 hours ago

AbCellera Biologics Slides: Study result


AbCellera price target raised to $9 from $8 at Stifel

2026-08-06T12:20:50.000Z - 4 days ago

AbCellera price target raised to $9 from $8 at Stifel


AbCellera Biologics Earnings Call Transcript: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Earnings Call Transcript: Q2 2026


AbCellera Biologics Slides: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Slides: Q2 2026


AbCellera Biologics Earnings release: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Earnings release: Q2 2026


AbCellera Biologics Quarterly report: Q2 2026

Aug 5, 2026, 5:00 PM EDT - 5 days ago

AbCellera Biologics Quarterly report: Q2 2026


AbCellera Reports Q2 2026 Business Results

Aug 5, 2026, 4:05 PM EDT - 5 days ago

AbCellera Reports Q2 2026 Business Results


AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 4 weeks ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 5 weeks ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 5 weeks ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 2 months ago

AbCellera appoints Victor Sandor to board of directors


AbCellera Appoints Dr. Victor Sandor to its Board of Directors

Jun 5, 2026, 9:00 AM EDT - 2 months ago

AbCellera Appoints Dr. Victor Sandor to its Board of Directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 3 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 3 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 3 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Slides: Corporate presentation

May 1, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 3 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 7 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 9 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 9 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 9 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


tradersunion353
tradersunion353 Aug. 10 at 9:21 PM
$ABCL what a unimpressive move who cares how good data is when stock does not benefit real share holders clowns here are just married to ABCL . they are not real share holders
0 · Reply
ShangVXO
ShangVXO Aug. 10 at 9:19 PM
Been tapped into @_ProfessorGamma for a minute now. The way they spot some of these plays before they run is nuts! Wise to be paying attention to this account, give him a proper follow 👍 $HIMS / $ABCL profit makers
0 · Reply
Instwr
Instwr Aug. 10 at 9:16 PM
$ABCL price target moved to 30$ by TRUIST analysts!
0 · Reply
dzetom
dzetom Aug. 10 at 9:10 PM
$ABCL If the 12-week data preserve efficacy, Phase III design is agreed with FDA without complications, and liver safety remains clean, I think a rerating into the $20–25 range before approval becomes quite plausible. Actual approval with genuinely best-in-class Phase III data could eventually justify a valuation well above $25, particularly because ABCL would then also have validated its broader internal drug-development platform.
0 · Reply
Stef_Gee
Stef_Gee Aug. 10 at 9:10 PM
$ABCL 🤔
1 · Reply
Stocktradesmoon
Stocktradesmoon Aug. 10 at 8:56 PM
$ABCL $ABCL Two new analyst rating updates today: 5-star analyst Debanjana Chatterjee upgrades her street high target from $13 to $25. 5-star analyst Srikripa Devarakonda reiterates a buy rating:
0 · Reply
jerrybe5000
jerrybe5000 Aug. 10 at 8:52 PM
$ABCL surprised they haven’t announce a share issuance yet!
0 · Reply
saleen18
saleen18 Aug. 10 at 8:50 PM
$ABCL People taking pills now for hot flashes is next level. My wife just uses ice packs
1 · Reply
Jwa68
Jwa68 Aug. 10 at 8:43 PM
$ABCL Nice tape boys. As anticipated.
1 · Reply
Money_maker777
Money_maker777 Aug. 10 at 8:36 PM
$ABCL Huge day for us holders. TradingView bumped their 1 year max target to $30, and that’s them being conservative the momentum we’re seeing could push us there way sooner. This one has real long term potential. And to all the new watchers showing up today, welcome to the party.
0 · Reply
PattyBergeron
PattyBergeron Aug. 10 at 8:30 PM
$ABCL i expect it could cool off. Important to remember though this company is still in its infancy with huge potential upside. This data came in better than expected. Im not really nerdy with the science but my understanding is this drug targets a very narrow metabolic pathway target. One that is recognized but has been illusive to make work with previous attempts. So in essence, ABCL shot a bullseye 🎯 by getting this result. This validates the proprietary tech stack they have developed and brings them up to a whole new level. This is truly groundbreaking and disruptive to all current antibody platforms. I look forward to holding this for a long time.
0 · Reply
Donniechen12345
Donniechen12345 Aug. 10 at 8:10 PM
$ABCL who the hell is keep selling ???
5 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 10 at 8:07 PM
$ABCL $25 seems like a no brainer. 🚀🚀
1 · Reply
Plan2TradeTrade2Plan
Plan2TradeTrade2Plan Aug. 10 at 8:06 PM
$ABCL AbCellera price target raised to $25 from $13 at JonesResearch https://www.tipranks.com/news/the-fly/abcellera-price-target-raised-to-25-from-13-at-jonesresearch-thefly-news
1 · Reply
Hnolove1984
Hnolove1984 Aug. 10 at 8:05 PM
$ABCL mooovee B****
0 · Reply
snowPOW
snowPOW Aug. 10 at 7:59 PM
0 · Reply
Donniechen12345
Donniechen12345 Aug. 10 at 7:56 PM
$ABCL afterhour party !$$$$$$ lets go !$$$
0 · Reply
Donniechen12345
Donniechen12345 Aug. 10 at 7:54 PM
$ABCL dude stop selling smh
0 · Reply
Donniechen12345
Donniechen12345 Aug. 10 at 7:50 PM
$ABCL dip then rip !!!!!! $$$$$$ aftrrhour party $$$$$$$$$$$$!!!!!!
0 · Reply
DeMampCamp
DeMampCamp Aug. 10 at 7:45 PM
$ABCL Prepare for analyst upgrades coming over the next couple of days!
1 · Reply
SwingTrades1
SwingTrades1 Aug. 10 at 7:43 PM
$ABCL That said, I wouldn’t get ahead of ourselves. The 12-week data are the next major piece of the puzzle. We know the four-week results were exceptional, with no sign of efficacy waning and, if anything, the effect still strengthening. The full 12-week dataset should help establish durability, determine whether monthly dosing is sufficient or potentially even allow for a longer dosing interval, and shape the Phase III design and regulatory discussions. In the meantime, I would expect the analysts covering ABCL to revisit their models and begin raising their price targets in the coming days as they digest the magnitude of these results. The key is seeing those actual revisions come through rather than relying on speculation.
0 · Reply
Stockholde
Stockholde Aug. 10 at 7:43 PM
$ABCL 12 price target was before the news now guess what it will be
0 · Reply